ORIGINAL ARTICLE

Comparison Between the Combination Therapy in Terms of Therapeutic Effectiveness and Anti-Microbial Efficacy in Extensive Drug-Resistant Acinetobacter Baumannii Infections

Naila Parveen[1], Rana Imran Sikander[1], Muhammad Zeeshan[2*], Syed Muneeb Ali[1], Muhammad Hassan[3]

ABSTRACT

Objective: To compare the clinical and antimicrobial efficacy of a triple-antibiotic regimen (Colistin, Cefoperazone/Sulbactam, and Tigecycline) with a double-antibiotic regimen (Colistin and Minocycline) for treating drug-resistant *Acinetobacter baumannii* infections in critically ill patients.

Study Design: A comparative cross-sectional study design.

Place and Duration of Study: The study was conducted at the Medical Intensive Care Unit (ICU) of Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan from April 2022 to October 2022.

Materials and Methods: A total of 38 patients aged 18-70 years admitted to the Medical Intensive Care Unit (ICU) of the Pakistan Institute of Medical Sciences, Islamabad gave consent to participate in the study. Any patient having a culture-proven polymicrobial infection was excluded. A total of 20 patients were allocated to Group A (triple-antibiotic regimen) and 18 patients to Group B (double-antibiotic regimen). Vital statistics were recorded daily, while laboratory-based biochemical markers (leucocyte count, CRP, lactate, procalcitonin) were recorded every 48 hours for ten days. Antimicrobial efficacy was assessed by a culture analysis on the 10th day.

Results: There were 20 patients in Group A and 18 in Group B. There were 32 patients with Ventilator-Associated Pneumonia (VAP), and six with bloodstream infection. No significant difference in the vitals and lab markers were found between the two groups. The only exception was serum lactate levels, which were significantly higher Group A (34.03 + 28.37 mg/dL), compared to Group B (16.11 $\pm$ 15.63 mg/dL; *p* = 0.024). Group A therapy was also found to have significantly improved antimicrobial efficacy in terms of positive-culture results (n=4, 20%) compared to Group B (n=10, 55.6%; *p* = 0.023).

Conclusion: The triple-antibiotic regimen had better antimicrobial efficacy than the double-antibiotic regimen for treating *Acinetobacter baumannii*-related infections.

Keywords: *Acinetobacter Baumannii, Ventilator Associated Pneumonia, Carbapenems, Multi Drug Resistant organisms.*

[1]Department of Critical Care/Internal Medicine[2]/Neurology[3] Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU) Pakistan Institute of Medical Sciences (PIMS) Islamabad, Pakistan

Correspondence:
Dr. Muhammad Zeeshan
Resident, Internal Medicine
Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU) Pakistan Institute of Medical Sciences (PIMS) Islamabad, Pakistan
E-mail: zeeshanchaudhry32.zc@gmail.com

Introduction

Antimicrobial-resistant infections have grown as a serious threat in recent times.[1] The more resistant microbes are identified as difficult-to-treat ESKAPE pathogens, including *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species.[2,3] Among these, *Acinetobacter baumannii* is now realized as a global threat, especially in intensive care units (ICUs), owing to a high morbidity and mortality rate.[4]

According to the latest guidelines regarding multidrug-resistant organisms (MDRO), novel β-lactam/β-lactamase inhibitors, especially ceftazidime–avibactam, are currently the treatment of choices for CRE and CRPA.[5-7] However, clinical isolates with resistance to novel β-lactam/β-lactamase inhibitors are emerging.[8] Carbapenem has been administered as an antibiotic for treating nosocomial infections. However, the high use of antimicrobials has led to carbapenem *resistant Acinetobacter baumannii* (CRAB) becoming common around the world.[9] The occurrence of CRAB has been reported to vary from 15 to 50% across Europe, and rates of more than 50% have been reported in the United States.[10,11] In South Korea, CRAB rates of about 90% have been reported.[12] There are no reported studies related to CRAB in Pakistan.

Ventilator-associated-pneumonia (VAP) is the most common health condition associated with *Acinetobacter baumannii*.[13] Colistin has been reported to show promising results for treating CRAB VAP.[14] However, with the widespread use of the drug, resistance has been developed to Colistin as well. A recent European multi-center trial investigated the antimicrobial susceptibility of *Acinetobacter baumannii* isolates collected from VAP affected patients. A 47.7% resistance to Colistin was reported in the study.[15] Evidence suggests that antibiotics are prescribed at a higher frequency in low and middle-income countries such as Pakistan compared to high-income countries.[16] This could have significant implications on the efficacy of the prescribed antibiotics in different populations. Different combinations of antibiotics have been used for managing CRAB-caused infections. However, the evidence regarding the efficacy of different antibiotic regimens is inconclusive.[17] Therefore, the efficacy of multi-drug regimens against *Acinetobacter baumannii* needs to be further explored. The current study assessed the clinical and antimicrobial efficacy of a triple regiment (Colistin, Cefoperazone/ Sulbactam, and Tigecycline) as compared to a double regimen (Colistin and Minocycline) in treating drug resistant *Acinetobacter baumannii* infections in patients admitted in the ICU in a hospital in Pakistan.

Materials and Methods

A comparative cross-sectional study design was conducted among patients admitted to the Medical Intensive Care Unit (ICU) of Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan, with proven XDR *A. baumannii* by culture and sensitivity. The study compared the outcomes of the combination therapy of antibiotics for XDR A baumannii. After approval of the ethical committee vide IERB certificate No.FMTI ERRB/07/02, this cross-sectional study was conducted from 30th April 2022 to 30 October 2022.Patients above 18 years of age, admitted to the ICU with any ailment, diagnosed with hospital-acquired XDR *A.* baumannii in the absence of a mixed bacterial infection with the targeted bacteria at the site of infection were included in the study. Any patient with severe liver cirrhosis (Child-Pugh class C), having a recent partial hepatic donation, or currently undergoing or with a history of liver transplantation was excluded from the study. Written, informed consent was taken from all patients. Patients were allotted code numbers. Patients with odd code numbers were placed in Group A, while those with even code numbers were placed in Group B. Patients in Group A were treated with an intravenous Colistin (9 million IU) loading dose; after 12 hours, maintenance of 3 million IU was administered every eight hours. In addition, a high-dose intravenous Tigecycline (200 mg) loading dose was given. After 12 hours, a maintenance dose of 100 mg was given. Also, 8 g Cefoperazone/ Sulbactam (2 + 2) was given every six hours. Patients in Group B with an intravenous loading dose of Colistin (9 million IU), followed after 12 hours by a maintenance dose of 3 million IU every eight hours. Moreover, a 200 mg oral, loading dose of Minocycline was given, followed after 12 hours by 100 mg every 12 hours.

In addition, the patient's name, gender, and diagnosis was recorded. Vital signs were measured to record vasopressor requirements. The vital signs were recorded daily. The biochemical parameters recorded were white blood cell counts, CRP levels, serum procalcitonin levels, and serum lactate levels. These parameters were recorded every 48 hours till the 10thth day. A successful clinical outcome was described as the resolution of signs and symptoms and improvement in the laboratory-based biochemical indicators. Microbial success was determined on a day-10 negative culture. If there was no improvement or the symptoms worsened

after 4-7 days of starting treatment, the case was considered therapeutic failure.

Data was entered and analyzed on SPSS v 26.0. Frequencies and percentages were described for categorical variables, such as gender and diagnosis. Mean and standard deviation were calculated for quantitative variables, such as the levels of the biochemical markers, age, and vital levels. Chi-squared test was applied to compare the microbial success. A p value of less than 0.05 was considered to be significant.

Results

A total of 38 patients were included in the study with 20 patients in Group A (triple-antibiotic regimen treatment group) and 18 in Group B (double-antibiotic regimen group). The mean age of the patients was 42.49 ± 19.60 years. There were 16 males and 21 females in the study. Age and gender were not reported for one patient. The age and gender of both groups has been shown in Table 1.

Table 1: Age and Gender of Both Groups (n = 37)

		Group A	Group B	Total	*P* Value
Age (Years)		44.10 ± 21.16	40.59 ± 18.06	42.49 ± 19.60	0.589
Gender	Male	9 (47.4%)	7 (38.9%)	16 (43.2%)	0.603
	Female	10 (52.6%)	11 (61.1%)	21 (56.8%)	

Table 2: Vitals and Laboratory-Based Biochemical Markers for Both Groups (n = 38; BP = Blood Pressure ; CRP = C-Reactive Protein)

	Group A	Group B	Total	*P* Value
Systolic BP (mm Hg)	105.40 ± 5.76	105.05 ± 9.74	105.23 ± 7.79	0.896
Diastolic BP (mm Hg)	59.37 ± 7.84	58.82 ± 6.71	59.11 ± 7.23	0.819
Heart Rate (/min)	114.23 ± 10.30	111.48 ± 15.88	112.89 ± 13.19	0.535
Temperature (^oC)	37.35 ± 0.77	37.64 ± 0.38	37.49 ± 0.63	0.152
Vasopressor (Days)	7.5 ± 5.15	6.56 ± 5.04	7.05 ± 5.05	0.572
White Blood Cells (/μl)	15976.57 ± 7214.82	16174 ± 5421.46	16070.37 ± 6343.88	0.924
CRP (mg/L)	95.87 ± 74.48	98.61 ± 54.74	97.17 ± 65.02	0.897
Lactate (mg/dL)	34.03 ± 28.37	16.11 ± 15.63	25.31 ± 24.50	0.024
Procalcitonin (mg/mL)	61.33 ± 231.60	121.54 ± 331.93	89.85 ± 281.23	0.517
Positive Culture	4 (20%)	10 (55.6%)	24 (63.2%)	0.023

The vitals and biochemical markers for both groups have been illustrated in Table 2.

There was no significant difference in the vital indicators between the two groups. Similarly, no significant difference was observed for the lab-based biochemical markers between the two groups, except for serum lactate levels which were significantly greater for patients in Group A (*p* = 0.024). A significantly greater number of positive culture samples were found for Group B (n = 10, 55.6%), compared to Group A (n = 4, 20%; *p* = 0.023), suggesting improved antimicrobial efficacy of the triple regimen antibiotics.

A total of 32 (84.2%) patients were diagnosed with VAP, while six (15.8%) had bloodstream infections. There was no difference in the diagnosis distribution between the two groups (*p* = 0.184), as shown in Figure 1.

Discussion

The present study found that *Acinetobacter baumannii-caused* bacteremia was still present in 63.2% (n = 24) of patients in both groups after ten days of therapy (Table 2). The triple-antibiotic regimen (positive culture cases after 10 days = 4, 20%) was found to have significantly better antimicrobial efficacy in comparison to the double-antibiotic regimen (positive culture cases after 10 days = 10, 55.6%; *p* = 0.023). However, no difference

Fig 1: Frequency of VAP and Blood Stream Infections in Both Groups (n = 38)

in the clinical vital signs was found between the two groups. Paul et al. compared the efficacy of Colistin and Meropenem against Colistin alone in CRAB infections. A total of 406 patients were included in this randomized controlled trial (RCT). The study reported no difference in the efficacy of the two regimens.[18] Regimens using varying dosages have also been attempted in such cases. In a retrospective analysis, De Pascale et al. compared the efficacy of different dosages of Tigecycline in 100 treating CRAB-infected patients. Patients receiving high dosages of Tigecycline (200 mg loading loss, and 100 mg every 12 hours thereafter) were found to have better clinical efficacy against CRAB infections.[19] Jung et al. conducted a meta-analysis of 23 trials investigating the effectiveness of antibiotic regimens for treating severely ill pneumonia caused by CRAB. A total of 15 different regimens were compared in this analysis. The study found that Sulbactam had the highest efficacy in terms of reducing mortality. Fosfomycin and Colistin, high-dose Tigecycline, and Colistin have had the highest antimicrobial efficacy.[20]

In a multi-center trial investigating different regimens for treating CRAB-caused pneumonia, regimens including Minocycline were found to have the highest efficacy. Moreover, it was suggested that Colistin monotherapy does not have promising results in such cases.[17] ICU patients with Acinobacter colistin resistant infections have excessive mortality, and they often develop a fulminant form of sepsis that rapidly progresses to shock and eventually death.[21]

CRAB related infections have become an emerging problem at a global level. New antimicrobials such as Tazobactam have not been found to have significantly efficacious in managing these infections.[22] As a result, combination regimens are recommended in CRAB related infections.[23,24] Since the results of studies investigating the efficacy of CRAB infections are contradictory, this study set out to compare the efficacy of two different regimens.

Another notable feature in the patient population was the age of the selected participants.

A limitation of this study was the quasi-experimental

design. Also, a small sample of 38 was included due to limited resources. Also, age-wise comparisons were not made in this study. Future studies should adopt an RCT design, recruiting a larger sample size.

Conclusion

The triple-antibiotic regimen (Colistin, Cefoperazone /Sulbactam, and Tigecycline) was found to have significantly improved antimicrobial efficacy in comparison to the double-antibiotic regimen (Colistin and Minocycline). The triple-antibiotic regimen is recommended to be used in CRAB related pneumonia and bacteremia in intensive care patients.

REFERENCES

1. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. Journal of global infectious diseases. 2019; 11: 36-42. doi:10.4103/jgid.jgid_110_18

2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical infectious diseases. 2009; 48: 1-2. doi: 10.1086/595011

3. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. The Lancet infectious diseases. 2019; 19: 56-66. doi: 10.1016/s1473-3099(18)30605-4

4. Papathanakos G, Andrianopoulos I, Papathanasiou A, Priavali E, Koulenti D, Koulouras V. Colistin-Resistant Acinetobacter Baumannii Bacteremia: A Serious Threat for Critically Ill Patients. Microorganisms. 2020; 8: 287. doi: 10.3390/microorganisms8020287

5. Jansen M, Wahida A, Latz S, Krüttgen A, Häfner H, Buhl EM, et al. Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii. Scientific reports. 2018; 8: 14140. doi: 10.1038/s41598-018-32344-y

6. Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namıduru M. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. Journal of international medical research. 2013; 41: 1830-7. doi: 10.1177/0300060513496172

7. Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. Journal of Global Antimicrobial Resistance. 2021; 24: 136-47. doi: 10.1016/j.jgar.2020.08.021

8. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC infectious diseases. 2011; 11: 1-7. doi: 10.1186/1471-2334-11-109

9. Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerging microbes & infections. 2019; 8: 1747-59. doi: 10.1080/22221751.2019.1698273

10. Control ECfDPa. Surveillance of antimicrobial resistance in Europe 2018. 2019:110. https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2018.pdf

11. Bulens SN, Sarah HY, Walters MS, Jacob JT, Bower C, Reno J, et al. Carbapenem-nonsusceptible Acinetobacter baumannii, 8 US metropolitan areas, 2012–2015. Emerging infectious diseases. 2018; 24: 727-34. doi: 10.3201/eid2404.171461

12. Choi JY, Kwak YG, Yoo H, Lee SO, Kim HB, Han SH, et al. Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean Nosocomial Infections Surveillance System (KONIS). Journal of Hospital Infection. 2016; 92: 363-71. doi: 10.1016/j.jhin.2015.12.012

13. Lim SM, Abidin AZ, Liew SM, Roberts JA, Sime FB. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis. Journal of infection. 2019; 79: 593-600. doi: 10.1016/j.jinf.2019.09.012

14. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiology & Infection. 2013; 141: 1214-22. doi:10.1017/s095026881200194x

15. Nowak J, Zander E, Stefanik D, Higgins PG, Roca I, Vila J, et al.

High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. Journal of Antimicrobial Chemotherapy. 2017; 72: 3277-82. doi: 10.1093/jac/dkx322

16. Atif M, Azeem M, Sarwar MR, Shahid S, Javaid S, Ikram H, et al. WHO/INRUD prescribing indicators and prescribing trends of antibiotics in the Accident and Emergency Department of Bahawal Victoria Hospital, Pakistan. Springerplus. 2016; 5: 1-7. doi: 10.1186/s40064-016-3615-1

17. Seok H, Choi WS, Lee S, Moon C, Park DW, Song JY, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea. Journal of Global Antimicrobial Resistance. 2021; 24: 429-39. doi: 10.1016/j.jgar.2021.01.018

18. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. The lancet Infectious diseases. 2018; 18: 391-400. doi: 10.1016/s1473-3099(18)30099-9

19. De Pascale G, Montini L, Pennisi MA, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care. 2014 ; 18: 1-9. doi: 10.1186/cc13858

20. Silversides JA, Pinto R, Kuint R, Wald R, Hladunewich MA, Lapinsky SE, et al. Fluid balance, intradialytic hypotension, and outcomes in critically ill patients undergoing renal replacement therapy: a cohort study. Critical care. 2014; 18: 1-0. doi: 10.1186/s13054-017-1916-6

21. Yang KY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, et al. Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study. Journal of Intensive Care. 2023; 11: 1-3. doi: 10.1186/s40560-022-00647-y

22. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clinical Infectious Diseases. 2016; 63: 234-41. doi: 10.1093/cid/ciw243

23. O'Donnell JN, Putra V, Lodise TP. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2021; 41: 762-80. doi: 10.1002/phar.2607

24. Bartal C, Rolston KV, Nesher L. Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options. Infectious diseases and therapy. 2022; 11: 683-94. doi: 10.1007/s40121-022-00597-w

....